Wanguiyuan Precision Technology, a pioneer in making homegrown microfluidics, is shining brighter than ever thanks to its high-speed automated production lines for medical equipment
Suzhou Wanguiyuan Precision Technology (Chinese: 苏州万贵源精密科技有限公司) completed its Series A financing round valued at tens of millions of CNY recently.
This round was led by Dongyun Venture Capital (Chinese: 东运创投) and supported by Qianrongchuanghe Capital (Chinese: 乾融创禾资本) and Sihaixincai Fund (Chinese: 四海新材基金).
The funding will be used to promote the productivity of current production lines, develop new product pipelines, construct new manufacturing bases and expand the research team.
Wanguiyuan, located in Wujiang of eastern China’s Suzhou City, is an intelligent medical technology solution provider for in vitro diagnosis, life sciences and biomedicines.
The “Microfluidics-enabled Automated Production Line” developed by Wanguiyuan ended the foreign monopoly of the microfluidic technology, which is widely applied in molecular and DNA diagnosis.
Wanguiyuan has become a pioneer in indigenously produced microfluidics. To date, it has manfactured more than 50 million packs of nucleic acid testing kits through such production lines.
The biotech startup has also invested in biomedicine and high-value medical equipment. It has already been working on “Sterile High-quality Wet Film Automated Production Lines,” “Cell Cultivation Automated Production Lines” and other related production lines, which will add to its core competence over time.